BOS 228

Synonym(s): ancremonam  |  LYS228

Class: Beta-lactam (monobactam)

Spectrum of activity:	Gram-negative
Details of activity:	Active against Enterobacteriaceae
Description:	Indicated for urinary tract infections and complicated intraabdominal infections
Institute where first reported:	Boston Pharmaceuticals (Licensed from Novartis AG)
Highest developmental phase:	Phase 2
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C1CC1(C(=O)O)O/N=C(/C2=CSC(=N2)N)\C(=O)N[C@H]3[C@@H](CN4CCOC4=O)N(C3=O)S(=O)(=O)O
Isomeric SMILES:	C1CC1(C(=O)O)O/N=C(/C2=CSC(=N2)N)\C(=O)N[C@H]3[C@H](N(C3=O)S(=O)(=O)O)CN4CCOC4=O
InChI:	InChI=1S/C16H18N6O10S2/c17-14-18-7(6-33-14)9(20-32-16(1-2-16)13(25)26)11(23)19-10-8(5-21-3-4-31-15(21)27)22(12(10)24)34(28,29)30/h6,8,10H,1-5H2,(H2,17,18)(H,19,23)(H,25,26)(H,28,29,30)/b20-9-/t8-,10+/m1/s1
InChI Key:	FWTGYTRQUBRVDW-NRABZWKMSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/118379834

External links:
Guide to Pharmacology:	ancremonam
Main Source:	https://www.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals
Citations:	https://aac.asm.org/content/62/10/e01200-18 https://aac.asm.org/content/63/7/e02592-18